Real-time Intraoperative Breast Cancer Visualization for Margin Assessment

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-01-27. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerto determinedetermine thestagebiopsy
  Phrases that lowered it: clinical20days beforeinvestigatorsdiagnosed
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Number of arms: 5 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Responsible party: sponsor investigator (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Primary purpose: diagnostic (lowers risk) · Design
• Design: sequential (lowers risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Allocation: non randomized (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer NCT05900986 · started 2023 · scored riskier than 78% of active trials completed
• Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery NCT02496065 · started 2015 · scored riskier than 33% of active trials completed
• Fluorescence Guided Surgery in Breast Cancer NCT02583568 · started 2015 · scored riskier than 88% of active trials completed
• Feasibility Study of Intraoperative Imaging in Breast Cancer NCT02438358 · started 2015 · scored riskier than 83% of active trials completed
• VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer NCT01508572 · started 2011 · scored riskier than 43% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.